Skip to main content
Clinical Trials/NCT02020681
NCT02020681CompletedNot Applicable

Effect of Curodont Repair or Placebo on the Remineralisation in Patients With Class 5 Carious Lesions: A Mono-centre, Split-mouth, Double-blinded, Placebo Controlled, Randomised, Post Marketing Clinical Study

Credentis AG1 site in 1 country40 target enrollmentStarted: September 1, 2013Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
40
Locations
1
Primary Endpoint
The primary efficacy outcome is the difference of the change in the lesion size assessed by morphometry (standardised pictures) between investigational medical device and placebo group.

Study Overview

Brief Summary

The purpose of this study is to evaluate the therapeutic benefit of Curodont Repair for the treatment of early buccal carious lesions compared to placebo.

Detailed Description

All study participants must have two early class V carious lesions in need of a treatment but not of an invasive treatment (split-mouth design). One lesion will be treated with Curodont Repair and one with placebo as control (single application). 3 months later fluoride (Duraphat) will be applied on both lesions. Study duration is 9 months. For assessment visual and tactile evaluation, pictures, ECM, Diagnodent Pen, Canary System, VAS is used.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Triple (Participant, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
14 Years to 65 Years (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Two class V carious lesions which do not require an invasive treatment
  • •Size and form of the lesions: the lesions must both be fully visible and assessable and accessible
  • •Patients must be able and willing to observe good oral hygiene throughout the study
  • •≥ 20 teeth
  • •Permanent dentition and ≤ 65 years
  • •Willing and able to attend the on-study visits
  • •Willing and able to understand all study-related procedures
  • •Written informed consent before participation in the study
  • •Negative pregnancy test for women of childbearing potential

Exclusion Criteria

  • •The two study lesions must not be on adjacent teeth
  • •No adjacent restoration on study tooth surface
  • •Fluoride varnish application < 6 months prior to study treatment
  • •Patient suffers from diabetes
  • •Evidence of tooth erosion (due to excessive acidic drink consumption or reflux)
  • •History of head and neck illnesses (e.g. head/neck cancer)
  • •Any pathology or concomitant medication affecting salivary flow or dry mouth
  • •Any metabolic disorders affecting bone turnover
  • •Concurrent participation in another clinical trial with an investigational drug or device or participation in another clinical trial with an investigational drug or device within 30 days prior to study entry
  • •Pregnant and lactating woman

Arms & Interventions

Curodont Repair

Experimental

Single application of Curodont Repair on treatment day D0 followed by a single application of fluoride (Duraphat) on D90.

Intervention: Curodont Repair (Device)

Curodont Repair

Experimental

Single application of Curodont Repair on treatment day D0 followed by a single application of fluoride (Duraphat) on D90.

Intervention: Fluoride (Device)

Placebo

Placebo Comparator

Single application of Placebo on treatment day D0 followed by a single application of fluoride (Duraphat) on D90.

Intervention: Placebo (Other)

Placebo

Placebo Comparator

Single application of Placebo on treatment day D0 followed by a single application of fluoride (Duraphat) on D90.

Intervention: Fluoride (Device)

Outcomes

Primary Outcomes

The primary efficacy outcome is the difference of the change in the lesion size assessed by morphometry (standardised pictures) between investigational medical device and placebo group.

Time Frame: D0, D30, D90, D270

Change of lesion size relative to baseline between study groups and different time points

Secondary Outcomes

  • Difference in the change of Diagnodent Pen values between investigational medical device and placebo group.(D0, D30, D90, D180, D270)
  • Change in lesion's progression assessed by VAS between investigational medical device and placebo group.(D0, D30, D90, D180, D270)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials